How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with Diffuse Large B Cell Lymphoma
The treatment of diffuse large B cell lymphoma (DLBCL) is generally based on multidrug chemotherapy, for instance the therapy with rituximab together with cyclophosphamide, vincristine, doxorubicin, and prednisone (R-CHOP). A significant proportion of DLBCL patients benefit from rituximab-based chemoimmunotherapy. However, among patients with DLBCL toxic effects due to therapy treatment are still very frequent, as well as inter-individual differences in the outcomes of patients even having similar stage, histological grade and histopathological type of the tumor.
Source: Blood Reviews - Category: Hematology Authors: Angela Falduto, Francesco Cimino, Antonio Speciale, Caterina Musolino, Sebastiano Gangemi, Antonella Saija, Alessandro Allegra Tags: Review Source Type: research
More News: Allegra | Chemotherapy | Genetics | Hematology | Lymphoma | Prednisone | Rituxan | Toxicology